• US: +1 9176726599
  • Login

Anthrax Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type (Cell-free PA Vaccines, Live Vaccines), By End-User(Specialty Center, Hospitals, Others), By Distribution Channel And Region Forecasts, 2023 - 2032

Format: PDF | Pages: 333 | Report ID: MRS1079


Report Description

According to estimates, the market for anthrax vaccines would be worth USD 10.14 billion in 2022 and USD 14.83 billion in 2032, growing at a CAGR of 11.6% between 2023 and 2032.

Market Dynamics

Because of the increased occurrence of anthrax, the vaccine industry is quickly rising. The growing habit of consuming raw and uncooked meat from sick animals is a key driving force in the global industry. Furthermore, an increase in the manufacture and industrialized processing of infected animal commodities such as wool, hair, and hide boosts market development considerably. Anthrax is more common in wild wildlife and cattle. The percentage of rural is growing as animal farming becomes more popular across the world. Individuals working on farms come into close contact with animals and are thus at significant risk of contracting anthrax. This aspect is a major market-main driver.

Furthermore, the cost-effectiveness of vaccines, new funding possibilities from the administration, research foundations, and contributors, as well as advancements in manufacturing and development technologies, are expected to drive market expansion throughout the projected period. Furthermore, the availability of a big target audience in developing regions fuels market expansion. However, because of the low percentage of voluntarily testing for anthrax illness, the industry for anthrax vaccines may experience a significant increase. Furthermore, a lack of knowledge regarding anthrax diagnostics in nations such as Africa renders it difficult for enterprises to directly approach their clients in such nations and areas, hampered market growth.

The worldwide anthrax vaccines industry is divided into five regions. The North American industry for anthrax vaccinations is the largest. In respect of income, the United States dominates the North American market. The European market is quickly rising because to a growing population of patients, particularly in the United Kingdom and Germans. Asia - Pacific region and Latin American markets are expected to grow considerably in the foreseeable future. Emerging countries including India and China are expected to support the growth of the Apac Region among 2020 and 2025, mainly due to better healthcare facilities, wealth creation, a rise in the amount of health coverage payers, the expansion of the personal healthcare industry, and increased awareness in these nations.

The Anthrax Vaccine market is fragmented into the Vaccine Type, application, end-user, and Distribution Channel segments. Based on the Vaccine Type, the cell-free PA vaccine is anticipated to dominate the market over the forecast period. Based on application, as a large number of anthrax vaccinations are used for livestock, the animal usage sector leads the anthrax vaccine industry. Up to 20percent of anthrax infections in humans result in mortality. As a result, the animal usage segment has expanded. In terms of the end-use segment, the hospital segment dominated the global market and is anticipated to continue its dominance over the forecast period.

The anthrax vaccine industry is concentrated, with only a few companies in both the people and veterinary segments. Major players lead the industry in respect of market size. With the growing frequency of illness and awareness campaigns, several new companies may come into the market throughout the projection period.

The report begins with an overview of the Industry Chain structure, and describes the industry environment, then analyses market size and forecast of Anthrax Vaccines by Vaccine Type, region, End-user, Distribution Channel, and application. In addition, this report introduces the market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.):

  • Merck & Co., Inc., 
  • Emergent Bio-Solutions
  • Zoetis, Inc.
  • PharmAthene, Inc
  • Biogenesis Bago S.A
  • Porton Biopharma Limited
  • Colorado Serum
  • Merial, Inc.
  • Tiankang
  • Agrovet
  • Biogenesis Bago
  • Bayer AG
  • Indian Immunologics

 Vaccine Type Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Cell-free PA Vaccines
  • Live Vaccines

 End-user Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Specialty Center
  • Hospitals
  • Others

 Distribution Channel Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Retail Pharmacy
  • Hospital Pharmacy
  • Others

Application Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Animal Use
  • Human Use

Region Coverage (Regional Consumption, Demand & Forecast by Countries, etc.):

  • North America (U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain, etc.)
  • Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
  • South America (Brazil, Mexico, Argentina, etc.)
  • Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa, etc.)

Frequently Asked Questions

The market for anthrax vaccine is anticipated to reach USD 10.14 billion in 2022 and grow at a CAGR of 11.6% from 2023 to 2032 to reach USD 14.83 billion in 2032.
North America generated the most revenue in 2021, and it is anticipated that it will hold this position throughout the study period.
The key players in the anthrax vaccine market include Merck & Co., Inc., Emergent Bio-Solutions, Zoetis, Inc., Pharm Athene, Inc, Biogenesis Bago S.A, Porton Biopharma Limited
Asia Pacific (especially China, and India) region is projected to grow at the fastest growth rate during the study period.
The anthrax vaccine industry \growing frequency of illness and awareness campaigns, several new companies may come into the market throughout the projection period.

Why Choose Market Research Strategy?

  Authenticated Data Sources

We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports

  Express Delivery

We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround

  Gain Instant Access

Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.

  Our Pledge to You

We abide by the information security policy and adheres to keep your private and business information confidential and secure.

Copyright © 2022 Market Research Strategy, All rights reserved.